Health Boards
Following on from this report Taltz (ixekizumab) gets FDA approval for Psoriasis Taltz (ixekizumab) has now also been given approval for psoriasis in the EU.
Source: pmlive.com
Quote:
Lilly is expecting to start rolling out Taltz in EU countries from this summer and through to the end of 2018, taking into account the typical cycle times for reimbursement assessment.
The approved dosing regimen for Taltz is a 160mg subcutaneous injection, followed by an 80mg injection every two weeks for 12 weeks and then a maintenance dose of 80mg each month. In trials, around 90% of patients treated with Lilly's drug had a 75% or more clearance in skin lesions after 12 weeks, with the majority (80%) showing clear or almost clear skin.
While second to market after Cosentyx, some clinicians say the phase III data for the two drugs suggest that Taltz may have some efficacy advantages over Novartis' product - though no head-to-head comparison is available - and could allow it to mount a strong challenge.
Source: pmlive.com